close

Marshall Edwards, Inc., a developmental stage pharmaceutical company, engages in the development and commercialization of drugs for the treatment of cancer. The company involves in the clinical development of a drug candidate called phenoxodiol, which is undergoing a pivotal Phase III study in combination with carboplatin in women with platinum-resistant ovarian cancer; in Phase I study for use in squamous cell carcinoma of the cervix, vagina, and vulva; and in Phase II clinical trials for the treatment in men with early stage disease. It is also developing two other anti-cancer compounds, including triphendiol, for pancreatic and bile duct cancer and has completed two Phase I human clinical trial; and NV-143, which is targeted for the treatment of melanoma, glioma, prostate, ovarian, and breast and lung cancer and is in the pre-clinical testing stage. The company was founded in 2000 and is based in North Ryde, Australia. Marshall Edwards, Inc. is a subsidiary of Novogen Limited.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	0.75
Volume	66994
Volume Avg	98887
52 Week High	3.28
52 Week Low	0.71
PE	N/A
PE (group average)	39
EPS Year	-0.65
EPS change Q/Q	-35.71%
EPS change Q/Q Yr ago	-40%
EPS change Q/Q next Q est	100%
EPS change Y/Y	-67.02%
REV change Q/Q	0%
REV change Q/Q Yr ago	0%
EPS next Q est	0.00
EPS next Y est	-0.43
Divident Annual	0.00
Dividend Yield	0%